Don Dizon, MD of Massachusetts General Hospital gives an overview of the SOLO2 Trial and the use of olaparib in ovarian cancer. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.
Olaparib and SOLO2 Trial: 52% of Patients Had a Partial Response
